Oct 13, 2008 - Biodel Inc. announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.
The details can be read here.
No comments:
Post a Comment